Chart of the Day: Viking Therapeutics (VKTX)
The pullback in obesity drug stocks is excessive. But as we’re also starting to see, short-lived. Look at Eli Lilly (LLY). Earlier this month, LLY dropped from about $750 to $625 after its oral weight-loss drug trial results disappointed investors. In...










